Cannabis and Hemp Sector Ideas

[gfp927z]

>>> Will Cannabis Be The Biggest Thing In Biotech For 2015?


http://finance.yahoo.com/news/cannabis-biggest-thing-biotech-2015-135600900.html



CORAL GABLES, FL / ACCESSWIRE / January 22, 2015 / Attention on marijuana stocks has increased since Colorado legalized it for recreational use in 2014. With larger institutional investment flowing into the industry, there's no doubt that this may be just the beginning for stocks in this sector. With 2016 slated as the next vote for more states to come online for legalization of medical and recreational licensing, much speculation has given rise to where to invest as it would appear not many new developments may come about until more states can come online. Biotech has been one of the identified target markets as regulation does not limit these organizations to particular state laws but more on the Federal side, specifically the FDA. From prescription sprays to cannabinoid oils, the biotech space may offer potential investment opportunity prior to the next vote.

Oxis International Inc. (OXIS) CEO, Tony Cataldo, was recently featured in an interview with The Wolf of Weedstreet where they discussed plans for future growth in the company. Mr. Cataldo previously helped build another small cap biotech company (at the time) into a much larger organization by the time he had moved onto his next project. In the interim, the company, under Cataldo's watch, has begun to build a stronger Scientific Advisory Board which will initially focus on the application of CBD's for those who suffer from multiple myeloma. After seeing highs near $0.04 over the last few weeks, investors are finding support levels and heavy accumulation at $0.025.

Peak Pharmaceuticals, Inc. (CTCO) recently signed a worldwide license agreement with Canna-Pet LLC and a cultivation agreement with a Colorado-based hemp farm. The stock has enjoyed a surge of buying volume which sent prices up by as much as 120% during the month. According to the American Pet Products Association, the U.S. pet industry has grown at an 8% CAGR to reach $58.51 billion by 2014 which puts Peak in position to capitalize on a fairly untapped niche through its focus on cannabis application for pets.

But just because cannabinoids are gaining mass appeal does not mean traditional biotechs are loosing their luster. Cellceutix Corporation (CTIX) has seen an incredibly volatile and volume filled market recently. This week the stock has rebounded by as much as 57% from Tuesday lows. Wednesday's late afternoon trading saw a pullback in the stock to close at $3.69. Today Cellceutix announced results of its recently completed phase 2b clinical trial will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015.

About marijuanastocks.com

MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

DAMJ VENTURES LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

<<<